Ameriprise’s GenMark Diagnostics, Inc GNMK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q2
Sell
-94,543
Closed -$2.26M 4037
2021
Q1
$2.26M Sell
94,543
-360,151
-79% -$6.69M ﹤0.01% 2809
2020
Q4
$6.64M Sell
454,694
-285,429
-39% -$3.78M ﹤0.01% 2063
2020
Q3
$10.5M Buy
740,123
+1,501
+0.2% +$22.9K ﹤0.01% 1527
2020
Q2
$10.9M Buy
738,622
+675,250
+1,066% +$6.86M ﹤0.01% 1481
2020
Q1
$262K Buy
63,372
+6,649
+12% +$31.2K ﹤0.01% 3355
2019
Q4
$273K Buy
56,723
+15,614
+38% +$86.1K ﹤0.01% 3507
2019
Q3
$249K Buy
+41,109
New +$257K ﹤0.01% 3498
2019
Q2
Sell
-51,986
Closed -$369K 3820
2019
Q1
$369K Sell
51,986
-61,189
-54% -$403K ﹤0.01% 3380
2018
Q4
$550K Buy
+113,175
New +$589K ﹤0.01% 3155
2017
Q3
Sell
-43,141
Closed -$510K 3788
2017
Q2
$510K Buy
43,141
+9,196
+27% +$118K ﹤0.01% 3229
2017
Q1
$435K Buy
+33,945
New +$409K ﹤0.01% 3223
2014
Q4
Sell
-331
Closed -$3K 4629
2014
Q3
$3K Sell
331
-356,356
-100% -$3.83M ﹤0.01% 5317
2014
Q2
$4.83M Sell
356,687
-168,992
-32% -$1.76M ﹤0.01% 2099
2014
Q1
$5.22M Buy
525,679
+252,139
+92% +$3.13M ﹤0.01% 1988
2013
Q4
$3.64M Buy
273,540
+271,304
+12,133% +$3.29M ﹤0.01% 2186
2013
Q3
$27K Buy
2,236
+421
+23% +$4.51K ﹤0.01% 4213
2013
Q2
$19K Buy
+1,815
New +$25K ﹤0.01% 4326

Ameriprise's GNMK Position: Q2 2021 in Review

Ameriprise sold out of GenMark Diagnostics, Inc (GNMK) in Q2 2021, closing a stake of 94,543 shares — an estimated $2.26M sold.

Ameriprise first reported a position in GNMK in Q2 2013 and held it in 17 quarters. The position peaked at $10.9M in Q2 2020. 0 funds tracked by Wall St. Rank hold GNMK as of Q2 2021.

  • Ameriprise reported no remaining GenMark Diagnostics, Inc position as of Q2 2021 after selling out during the quarter.
  • Ameriprise sold 94,543 GenMark Diagnostics, Inc shares in Q2 2021, an estimated $2.26M.
  • Ameriprise first reported a position in GenMark Diagnostics, Inc in Q2 2013 and held it in 17 quarters.
  • Ameriprise's GenMark Diagnostics, Inc position peaked at $10.9M in Q2 2020.
  • 0 funds tracked by Wall St. Rank held GenMark Diagnostics, Inc as of Q2 2021.

Based on Ameriprise's 13F filing for Q2 2021, filed 16 Aug 2021.